Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis

Patients with hematological malignancy and COVID-19 display a high mortality rate. In such patients, immunosuppression due to underlying disease and previous specific treatments impair humoral response, limiting viral clearance. Thus, COVID-19 convalescent plasma (CCP) therapy appears as a promising...

Full description

Saved in:

Bibliographic Details
Published in:	Leukemia Vol. 36; no. 4; pp. 1025 - 1034
Main Authors:	Hueso, Thomas, Godron, Anne-Sophie, Lanoy, Emilie, Pacanowski, Jérôme, Levi, Laura I, Gras, Emmanuelle, Surgers, Laure, Guemriche, Amina, Meynard, Jean-Luc, Pirenne, France, Idri, Salim, Tiberghien, Pierre, Morel, Pascal, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Hermine, Olivier, Gagneux-Brunon, Amandine, Freymond, Nathalie, Grabar, Sophie, Lacombe, Karine
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.04.2022
Subjects:	Antibodies, Viral Blood pressure CD20 antigen Coronaviruses COVID-19 COVID-19 - therapy Hematology Humans Hypertension Immune clearance Immune response Immune response (humoral) Immune system Immunization, Passive Immunosuppression Immunotherapy Lymphocytes B Malignancy Medical treatment Monoclonal antibodies Mortality Neoplasms Patients Propensity Score SARS-CoV-2 Sensitivity analysis Severe acute respiratory syndrome coronavirus 2 Subgroups Survival Tumors Viral diseases
ISSN:	0887-6924, 1476-5551, 1476-5551
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!